Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested

Information

  • Patent Grant
  • 6589206
  • Patent Number
    6,589,206
  • Date Filed
    Tuesday, October 10, 2000
    23 years ago
  • Date Issued
    Tuesday, July 8, 2003
    21 years ago
Abstract
A method and device for occluding a patient's ascending aorta, maintaining circulation of oxygenated blood in the patient and delivering cardioplegic fluid to arrest the patient's heart. An aortic occlusion catheter has an occluding member for occluding the ascending aorta. The aortic occlusion catheter passes through a cannula. Delivery of oxygenated blood is accomplished through either the cannula or the aortic occlusion catheter.
Description




BACKGROUND OF THE INVENTION




The present invention is directed to methods and devices for occluding a patient's ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested. Such devices and methods are useful for performing various procedures on a patient's vascular system and heart such as the procedures described in U.S. Pat. Nos. 5,584,803 and 5,682,906 which describe coronary artery bypass grafting (CABG) and valve procedures, respectively. Another device and method for occluding a patient's ascending aorta is described in Re. 35,352.




The methods and devices described in the above-mentioned patents use an internal occlusion device to occlude the ascending aorta rather than a conventional external cross-clamp. Use of an internal occlusion device may reduce strokes as compared to conventional external cross-clamps since external cross-clamps distort and compress the aorta which may release emboli leading to strokes.




It is an object of the invention to provide alternative methods and devices for occluding a patient's ascending aorta and maintaining circulation of oxygenated blood when the patient's heart is arrested.




SUMMARY OF THE INVENTION




In accordance with the object of the invention, the present invention provides alternative methods and devices for occluding a patient's ascending aorta and maintaining circulation of oxygenated blood in a patient when the patient's heart is arrested.




In a first preferred method and device of the present invention, an aortic occlusion device having a blood delivery lumen and an occluding member is introduced into the patient's aortic arch. The occluding member has an interior in fluid communication with the blood delivery lumen so that delivery of oxygenated blood inflates the occluding member. An advantage of this method is that a separate inflation lumen is not necessary. The aortic occlusion device preferably passes through a cannula having a y-arm with the aortic occlusion catheter passing through an arm of the y-arm. The other arm of the y-arm connector is coupled to the source of oxygenated blood so that bypass support can be maintained even when the aortic occlusion device has been removed.




In another preferred method and device, oxygenated blood is delivered to the patient through the aortic occlusion catheter. The aortic occlusion catheter also passes through a cannula with a y-arm connector so that bypass support can be maintained when the aortic occlusion device is removed. The aortic occlusion device also preferably includes a lumen for delivering cardioplegic fluid and venting the ascending aorta and a pressure lumen for measuring pressure in the ascending aorta. If the lumens are not provided in the aortic occlusion device, delivery of cardioplegic fluid, venting of the ascending aorta and pressure monitoring may be accomplished with the cannula.




In another preferred device, the aortic occlusion device has an occluding member mounted to a side of the catheter. The occluding member has a pathway therethrough which is in communication with a lumen in the aortic occlusion catheter. The pathway directs cardioplegic fluid toward the coronary ostia while the aortic occlusion device directs the oxygenated blood in the direction of normal blood flow in the aorta.











These and other aspects and advantages of the present invention will become apparent from the following description and drawings.




BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

shows an aortic occlusion device;





FIG. 2

is a cross-sectional view of a first step in forming the aortic occlusion catheter of

FIG. 1

;





FIG. 3

is a cross-sectional view of the structure of

FIG. 2

after heating;





FIG. 4

is a cross-sectional view of a further step in forming the aortic occlusion catheter of

FIG. 1

;





FIG. 5

is a cross-sectional view of

FIG. 1

along line I—I;





FIG. 6

shows a cannula;





FIG. 7

shows an enlarged view of the distal end of the cannula of

FIG. 6

;





FIG. 8

is a plan view of a ring;





FIG. 9

is a side view of the ring;





FIG. 10

shows a n introducer with an incising element in a retracted position;





FIG. 11

shows the introducer with the incising element in an exposed position;





FIG. 12

shows the aortic occlusion device and cannula passing through a penetration in the ascending aorta;





FIG. 13

shows another aortic occlusion device passing through the cannula and into the patient's ascending aorta;





FIG. 14

shows yet another aortic occlusion device;





FIG. 15

shows still another aortic occlusion device;





FIG. 16

shows a final aortic occlusion device;





FIG. 17

illustrates a preferred method of introducing the aortic occlusion device;





FIG. 18

shows another preferred aortic occlusion device with the balloon occluding the ascending aorta; and





FIG. 19

shows the aortic occlusion device of

FIG. 18

with the balloon deflated.











DESCRIPTION OF THE PREFERRED EMBODIMENTS




Referring to

FIGS. 1 and 5

, an aortic occlusion device


2


is shown. The aortic occlusion device


2


has an occluding member


4


configured to occlude a patient's ascending aorta. The occluding member


4


is preferably a balloon but may also be a mechanically actuated member. The aortic occlusion device


2


has an inflation lumen


6


for inflating the occluding member


4


, a pressure lumen


8


for measuring pressure in the ascending aorta, and a lumen


10


for delivering cardioplegic fluid and/or venting the ascending aorta. The aortic occlusion device


2


is preferably manufactured and used in the manner described in U.S. patent application Ser. No. 08/782,113 but may also be manufactured in any other manner such as an extrusion.




The aortic occlusion device


2


is preferably substantially straight in an unbiased position, however, the aortic occlusion device


2


may also have a shaped end. For example, the aortic occlusion catheter


2


can have an L-shaped end which facilitates positioning the occluding member


4


in the ascending aorta depending upon the surgical approach. The aortic occlusion device


2


is preferably flexible so that it can be bent as necessary without kinking.




Referring to

FIGS. 2-5

, a preferred method of forming the aortic occlusion device


2


is shown.

FIG. 2

shows a longitudinal cross-section of a tube


12


, preferably a urethane tube, mounted on a teflon-coated mandrel


14


with the elongate element


16


wound helically around the tube


12


. The elongate element


16


is preferably a wire ribbon having a thickness of 0.003 inch and a width of 0.012 inch. The elongate element


16


is preferably wrapped around the tube


12


with a spacing of 0.010 inch. Another tube


20


is positioned over the elongate member


16


and a shrink tube (not shown) is positioned over the tube


20


. The entire structure is then heated to fuse the tubes together to form a reinforced tube


22


which is shown in longitudinal cross-section in FIG.


3


. The resulting reinforced tube


22


preferably has an inner diameter of about 0.100 inch and a wall thickness of about 0.010 inch.




Referring to

FIG. 4

, a two-lumen member


24


is positioned against the reinforced tube


22


and a shrink tube


26


is positioned around the member


24


and reinforced tube


22


. The two-lumen member


24


has the inflation lumen


6


, which is used for inflating the occluding member


4


, and the pressure lumen


8


, which is used for pressure monitoring in the ascending aorta. The two-lumen member


24


is preferably an extrusion having a D-shaped outer surface in cross-section. The member


24


and tube


22


are then heated and the shrink tube


26


is removed to obtain the egg-shaped cross-sectional shape shown in FIG.


5


. The cross-sectional shape is preferably about 0.145 inch tall and 0.125 inch wide. The inflation lumen


6


is then pierced to provide an inflation path to the occluding member


4


and the occluding member


4


is then mounted to the shaft.




Referring to

FIGS. 6 and 7

, a cannula


28


is shown which is used to return oxygenated blood to the patient when the patient's heart is arrested. The aortic occlusion device


2


is introduced into the patient through the cannula


28


as will be described below. The cannula


28


has a y-arm connector


30


with first and second arms


32


,


34


with each coupled to a lumen


35


. The second arm


34


has a hemostasis valve


36


which may be any hemostasis valve and is preferably a Thouy-Borst valve. The cannula


28


has a reinforced body


38


which is preferably formed in the manner described in U.S. patent application Ser. No. 08/749,683, which is hereby incorporated by reference, however, any other method may be used including extrusion. The distal end


40


of the cannula


28


is beveled and has an open end


42


and two side ports


44


for infusing oxygenated blood into the patient. A radiopaque markers


45


are provided at the distal end for visualization as discussed below.




Referring to

FIGS. 6-9

, a ring


46


is attached to the distal end


40


of the cannula


28


. The ring


46


limits insertion of the cannula


28


into the vessel, stabilizes the cannula


28


, and receives purse-string sutures which provide hemostasis around the cannula


28


when the cannula


28


is positioned in a vessel. Referring to

FIGS. 8 and 9

, the ring


46


has slots


48


which may receive purse-string sutures as will be described below.




Referring to

FIGS. 10 and 11

, an introducer


50


is positioned in the cannula


28


to introduce the cannula


28


into a vessel. The introducer


50


has a connector hub


51


which is received by the hemostasis valve


36


on the second arm


32


of the cannula


28


to seal the space between the introducer


50


and cannula


28


. The introducer


50


has an incising element


52


for incising the vessel into which the cannula


28


is introduced. The incising element


52


is attached to a shaft


54


which is coupled to a trigger


56


for moving the incising element


52


from the retracted position of

FIG. 10

to the exposed position of FIG.


11


. An o-ring seals


58


the space between an outer housing


60


and the shaft


54


. The incising element


52


is biased toward the retracted position by a spring


62


so that the incising element


52


is only exposed when the trigger


56


is actuated. When introducing the cannula


28


into the vessel, the trigger


56


is actuated to move the incising element


52


to the exposed position, the vessel is incised with the incising element


52


and the cannula


28


is inserted through the incision. As will be described below, one or more purse-string sutures are then used to form a hemostatic seal around the cannula


28


. The incising element


52


may be omitted if a separate incising device is used.




Referring to

FIG. 12

, the cannula


28


is positioned in a patient's ascending aorta with the aortic occlusion device


2


passing through the hemostasis valve


36


. Placement of the cannula


28


and aortic occlusion device


2


into the position of

FIG. 12

is described below. Referring to

FIGS. 5 and 12

, the lumen


10


is coupled to a source of cardioplegic fluid


64


, the inflation lumen


6


is coupled to a source of inflation fluid


66


, and the pressure lumen


8


is coupled to the pressure monitor


68


for measuring pressure in the ascending aorta. The lumen


10


is also coupled to a vacuum source


70


for venting the ascending aorta.




The first arm


32


of the cannula


28


is coupled to a source of oxygenated blood


72


so that blood is delivered through the lumen


35


of the cannula


28


with the blood passing through the annular area between the cannula


28


and the aortic occlusion device


2


. The oxygenated blood passing through the open end


42


of the cannula


28


is directed at the occluding member


4


so that the oxygenated blood is not directed at the wall of the aorta. An advantage of directing the oxygenated blood at the occluding member


4


is that the fluid is dispersed radially outward by the occluding member


4


before coming into contact with the wall of the aorta. By directing the blood at the occluding member


4


, rather than at the wall of the aorta, the likelihood of releasing emboli from the wall of the aorta may be reduced. Oxygenated blood is also directed through the side ports


44


so that oxygenated blood is delivered to the patient even if the occluding member


4


blocks the open end


42


of the cannula


28


.




Referring to

FIG. 13

, another aortic occlusion device


2


A is shown having a balloon


76


which is inflated with the oxygenated blood delivered to the patient. The aortic occlusion device


2


A has a blood flow lumen


78


which is fluidly coupled to the interior of the balloon


76


for inflating the balloon


76


. Oxygenated blood is then delivered to the patient through an opening


80


, preferably a number of openings, in the balloon


76


. An advantage of the aortic occlusion device


2


A is that a separate inflation lumen is not required since occlusion is accomplished by simply delivering oxygenated blood through the aortic occlusion device


2


A. The aortic occlusion device


2


A may also include a pressure lumen


82


for measuring pressure in the ascending aorta and a lumen


84


for delivering cardioplege and venting the ascending aorta. The aortic occlusion device


2


A is preferably formed in the manner described above except that the lumen


78


is sized large enough to provide sufficient flow of oxygenated blood at an acceptable pressure. Acceptable blood flow rates and pressures are disclosed in the above-mentioned patents and patent applications which have been incorporated by reference. Although it is preferred to manufacture the device in the manner described above, the aortic occlusion device


2


A may also simply be an extrusion or laminated structure. The balloon


76


is preferably made of silicone having a thickness of between 0.005 and 0.009 inch.




The aortic occlusion catheter


2


A passes through the cannula


28


so that oxygenated blood can be delivered to the patient when the aortic occlusion device


2


A is removed. The cannula


28


is preferably the cannula


28


described above with the first arm


32


coupled to the source of oxygenated blood


72


, pressure monitor


68


, and source of cardioplegic fluid via valve


86


. Thus, cardioplegic fluid and oxygenated blood can be directed through the lumen


35


in the cannula


28


if the lumen


84


is not provided in the aortic occlusion catheter


2


A. The cannula


28


has the hemostasis valve


36


to seal the space between the cannula


28


and aortic occlusion device


2


A.




Referring to

FIG. 14

, yet another aortic occlusion device


2


B is shown. The aortic occlusion device


2


B has the occluding member


4


and the inflation lumen


6


coupled to the source of inflation fluid


66


for inflating the occluding member


4


. The aortic occlusion device


2


B also has a lumen


88


for delivering oxygenated blood to the patient from the source of oxygenated blood


64


. The shaft is preferably reinforced with a wire in the manner described above except that the lumen


88


is sized large enough to provide adequate blood flow to the patient at an acceptable pressure as discussed above. The cannula


28


is preferably the same as the cannula


28


described above and the aortic occlusion device


2


B is introduced through the cannula


28


in the manner described below. The first arm


34


of the cannula


28


has the hemostasis valve


36


for receiving the aortic occlusion device


2


B. The second arm


32


is coupled to a valve


90


which determines whether cardioplegic fluid or oxygenated blood is delivered through the lumen


35


in the cannula


28


. Valve


92


determines whether oxygenated blood is delivered through the lumen


35


in the cannula


28


or the lumen


88


in the aortic occlusion device


2


B. An advantage of the aortic occlusion device


2


B and cannula


28


is that bypass support can be provided before inflating the occluding member


4


and can also be maintained after the aortic occlusion device


2


B is removed from the cannula


28


.




Referring to

FIGS. 15

, another aortic occlusion device


2


C is shown. The aortic occlusion device


2


C has a balloon


94


mounted to a side of a shaft


96


. The aortic occlusion device


2


C has an inflation lumen


98


for inflating the balloon


94


through inflation outlet


100


and a lumen


102


for delivering cardioplegic fluid from the source of cardioplegic fluid


64


and venting the ascending aorta using the vacuum source


70


. The aortic occlusion device


2


C also has a blood flow lumen


104


for delivering oxygenated blood to the patient from the source of oxygenated blood


72


. A fluid path


106


passes through the balloon


94


which is in fluid communication with the lumen


102


so that cardioplegic fluid is delivered through the fluid path


106


in the balloon


94


. An advantage of the aortic occlusion device


2


C is that the cardioplegic fluid can be delivered toward the aortic valve while oxygenated blood is directed in the direction of normal blood flow in the aortic arch. The distal end of the aortic occlusion device has an open end


108


and side ports


110


through which the oxygenated blood is delivered. The aortic occlusion device


2


C also includes the ring


46


which is the same as the ring


46


described above. The aortic occlusion device


2


C may be manufactured in any manner such as the manner described above or as a simple extrusion or laminated structure.




Referring to

FIG. 16

, the aortic occlusion device


2


is shown passing through a side port


112


of a cannula


28


D. The side port


112


facilitates positioning the occluding member


4


in the ascending aorta. The aortic occlusion device


2


is preferably the aortic occlusion device


2


described above. The aortic occlusion device


2


passes through a lumen


114


in the cannula


28


D. The lumen


114


is coupled to the source of oxygenated blood


72


so that the oxygenated blood is delivered through the annular area between the aortic occlusion device


2


and the wall of the lumen


114


. The lumen


114


has an open end


116


with a cross-member


118


which prevents the aortic occlusion catheter


2


from passing through the open end


116


. An advantage of the side port


112


is that the aortic occlusion device


2


is directed into the ascending aorta while blood passing through the lumen


114


is directed in the direction of normal blood flow in the aorta.




Referring to

FIGS. 18 and 19

, another aortic occlusion device


2


E is shown. The aortic occlusion device


2


E is similar to the aortic occlusion device


2


A of

FIG. 13

in that balloon


130


is inflated with oxygenated blood delivered from the source of oxygenated blood


72


. Oxygenated blood is delivered to the patient through a lumen


132


and an open end


134


of the aortic occlusion device


2


E. As will be described below, the interior of the balloon


130


is fluidly coupled to the lumen


132


through an inflation hole


133


for inflating the balloon


130


when blood is delivered through the lumen


132


.




The aortic occlusion device


2


E includes a body


136


having the y-arm connector


30


described above. A sleeve


138


is positioned in the lumen


132


to control inflation and deflation of the balloon


130


. Blood passing through the lumen


132


passes through the sleeve


138


so that the sleeve


138


does not interfere with delivery of oxygenated blood to the patient. The sleeve


138


is attached to a rod


140


which is manipulated to move the sleeve


138


between the positions of

FIGS. 18 and 19

. The sleeve


138


has a hole


142


which is aligned with the inflation hole


133


as shown in

FIG. 18

to fluidly couple the interior of the balloon


130


with the lumen


132


. When the sleeve


138


is advanced to the position of

FIG. 19

, the hole


142


is not aligned with the inflation lumen


133


and the sleeve


138


covers the inflation hole


133


so that the interior of the balloon


130


is not fluidly coupled to the lumen


132


.




The sleeve


138


permits the surgeon to control inflation and deflation of the balloon


130


. After introduction of the aortic occlusion device


2


E, bypass support is generally initiated before inflating the balloon


130


. This can be accomplished by maintaining the sleeve


138


in the position of

FIG. 19

so that the balloon


130


is not inflated by the blood delivered through the lumen


132


. When it is desired to inflate the balloon


130


and occlude the ascending aorta, the sleeve


138


is moved to the position of

FIG. 18

so that the balloon


130


is inflated with blood. The sleeve


138


also permits the surgeon to maintain full occlusion of the ascending aorta even when blood flow is reduced to a level which would not provide sufficient pressure to inflate the balloon to maintain full occlusion of the aorta. In order to maintain occlusion at low flow rates, the sleeve


138


is moved to the position of

FIG. 19

before reducing the blood flow rate so that the balloon


130


will remain inflated when the delivery pressure drops. Finally, the sleeve


138


also permits the surgeon to maintain bypass support with a deflated balloon


130


after the surgical procedure is completed. In order to maintain deflation of the balloon while delivering blood, the blood flow rate is reduced to deflate the balloon


130


, the sleeve is moved to the position of

FIG. 19

to deflate the balloon, and the blood flow rate is then increased. The sleeve


138


prevents the balloon


130


from inflating when the blood flow rate is increased.




The body


136


may be made in any suitable manner and is preferably manufactured similar to the cannula


28


of

FIG. 6. A

support tube


144


is attached to the body and the balloon


130


is mounted to the support tube. A soft tip


145


is attached to the distal end of the support tube


144


to provide an a traumatic distal end to prevent injury during introduction of the device


2


E. The sleeve


138


may be made of any suitable material and is preferably a urethane tube. The rod


140


may also be made of any suitable material and is preferably urethane coated polyamide. Although it is preferred to provide the sleeve


138


between the interior of the balloon


130


and the lumen


132


any other device may be used such as a valve, balloon or plug.




Use of the cannula and aortic occlusion device


2


is now described in connection with

FIGS. 12 and 17

. The description below is applicable to all cannulae


28


,


28


D and aortic occlusion devices


2


,


2


A,


2


B,


2


C described herein. Although the method described below is for direct insertion of the cannula


28


and aortic occlusion device


2


into the aortic arch, the cannula


28


and aortic occlusion device


2


may also be introduced through a peripheral artery such as the femoral, subclavian or axillary arteries as described in U.S. Pat. No. 5,484,803.




Before introduction of the cannula, a rib retractor


120


or other device is used to form an opening in an intercostal space such as the 4


th


intercostal space. The opening through the intercostal space is used for access to perform a surgical procedure such as a valve repair or replacement. The opening also provides direct access to the ascending aorta for control of the ascending aorta and to place purse-string sutures in the aorta.




An incision is also created in the 1


st


or 2


nd


intercostal space in which an 11.5 mm trocar


122


is positioned. The cannula


28


is then introduced through the trocar


122


and advanced to the surface of the aorta with the introducer


50


(see

FIGS. 10 and 11

) positioned in the lumen


35


of the cannula


28


to determine the appropriate orientation of the cannula


28


. The distal end of the introducer


50


is then moved into contact with the aorta about 1-2 cm below the origin of the innominate artery to identify the appropriate location for purse-string sutures


124


. The surgeon then places two purse-string sutures


124


around the site. The ends of the purse-string sutures


124


are passed through tubes


126


which are used to tension the purse-string sutures


124


. The purse-string sutures


124


are then passed through the slots


48


in the ring


46


.




The cannula


28


is then advanced into contact with the aorta at the site now surrounded by the purse-string sutures


124


. The surgeon then incises the aorta with the incising element


52


of the introducer


50


or with a separate incising instrument. The cannula


28


is then immediately advanced through the incision until the ring


46


engages the aorta. The radiopaque marker


45


may be viewed under fluoroscopy and the cannula


28


manipulated until the beveled tip is directed toward the aortic valve. Alternatively, the tip orientation may be determined by TEE. The purse-string


124


sutures are then tensioned to seal around the cannula


28


. The aortic occlusion device


2


is then passed through the hemostasis valve


36


and advanced until the occluding member


4


is positioned in the ascending aorta. Delivery of oxygenated blood, occlusion of the ascending aorta and delivery of cardioplegic fluid is then performed in the manner described in U.S. Pat. No. 5,484,803.




Although the method described above positions the aortic occlusion device through an opening separate from the opening through which the surgeon operates, the cannula and aortic occlusion device


2


may also be introduced through the same opening through which the surgeon operates. The choice of opening location, number and size are a matter of surgical choice depending upon patient anatomy, the medical procedure being performed, surgeon preference and the particular embodiment of the invention being used. Furthermore, the devices described herein may have application in other parts of the heart and in other parts of the body. Thus, the description of the specific procedure described above is merely an example and other surgical methods may be used with the devices and methods of the present invention.



Claims
  • 1. A system for occluding a patient's ascending aorta and delivering oxygenated blood to the patient, comprising:a cannula having a first lumen and a second lumen, the first lumen having a distal end for delivering oxygenated blood; an occluding member mounted to one side of the cannula at a location proximal the distal end, the occluding member being movable between a collapsed position and an expanded position, the occluding member having a pathway therethrough in fluid communication with the second lumen, wherein the occluding member is a balloon.
  • 2. The system of claim 1, wherein the occluding member is configured to occlude the aorta at a location between the barchiocephalic arteries and the coronary ostia.
  • 3. The system of claim 2, wherein the occluding member is configured such that the cannula is located between the occluding member and the brachiocephalic arteries when the occluding member occludes the aorta at a location between the brachiocephalic arteries and the coronary ostia.
  • 4. The system of claim 1, wherein the cannula has a third lumen in fluid communication with the interior of the occluding member.
  • 5. The system of claim 4, comprising a source of cardioplegia fluid coupled to the second lumen.
  • 6. The system of claim 1, comprising a source of oxygenated blood coupled to the first lumen.
  • 7. The system of claim 1, wherein the distal end of the cannula has side ports.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 09/012,833, filed Jan. 23, 1998, now U.S. Pat. No. 6,159,178, issued Dec. 12, 2000, the entire disclosure of which is hereby incorporated by reference.

US Referenced Citations (239)
Number Name Date Kind
2308484 Auzin et al. Jan 1943 A
2854982 Pagano Oct 1958 A
3385300 Holter May 1968 A
3635223 Klieman Jan 1972 A
3674014 Tillander Jul 1972 A
3692018 Goetz et al. Sep 1972 A
3766924 Pidgeon Oct 1973 A
3769960 Robinson Nov 1973 A
3788328 Alley et al. Jan 1974 A
3833003 Taricco Sep 1974 A
3837347 Tower Sep 1974 A
3851647 Monestere, Jr. et al. Dec 1974 A
3889686 Duturbure Jun 1975 A
3903895 Alley et al. Sep 1975 A
3915171 Shermeta Oct 1975 A
3963028 Cooley et al. Jun 1976 A
3970090 Loiacono Jul 1976 A
3983879 Todd Oct 1976 A
4000739 Stevens Jan 1977 A
4019515 Kornblum et al. Apr 1977 A
4029104 Kerber Jun 1977 A
4073297 Kopp Feb 1978 A
4122858 Schiff Oct 1978 A
4154227 Krause et al. May 1979 A
4173981 Mortensen Nov 1979 A
4204328 Kutner May 1980 A
4248224 Jones Feb 1981 A
4276874 Wolvek et al. Jul 1981 A
4284073 Krause et al. Aug 1981 A
4285341 Pollack Aug 1981 A
4287892 Schiff Sep 1981 A
4289129 Turner Sep 1981 A
4290428 Durand et al. Sep 1981 A
4301803 Handa et al. Nov 1981 A
4304239 Perlin Dec 1981 A
4310017 Raines Jan 1982 A
4323071 Simpson et al. Apr 1982 A
4327709 Hanson et al. May 1982 A
4328056 Snooks May 1982 A
4351341 Goldberg et al. Sep 1982 A
4405313 Sisley et al. Sep 1983 A
4411055 Simpson et al. Oct 1983 A
4413989 Schjeldahl et al. Nov 1983 A
4417576 Baran Nov 1983 A
4430081 Timmermans Feb 1984 A
4439186 Kuhl Mar 1984 A
4441495 Hicswa Apr 1984 A
4451251 Osterholm May 1984 A
4456000 Schjeldahl et al. Jun 1984 A
4459977 Pizon et al. Jul 1984 A
4464175 Altman et al. Aug 1984 A
4493697 Krause et al. Jan 1985 A
4496345 Hasson Jan 1985 A
4497325 Wedel Feb 1985 A
4512762 Spears Apr 1985 A
4527549 Gabbay Jul 1985 A
4531935 Berryessa Jul 1985 A
4531936 Gordon Jul 1985 A
4535757 Webster, Jr. Aug 1985 A
4540399 Litzie et al. Sep 1985 A
4552558 Muto Nov 1985 A
4573966 Weikl et al. Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4596552 DeVries Jun 1986 A
4601706 Aillon Jul 1986 A
4601713 Fuqua Jul 1986 A
4610661 Possis et al. Sep 1986 A
4631052 Kensey Dec 1986 A
4639252 Kelly et al. Jan 1987 A
4648384 Schmukler Mar 1987 A
4664125 Pinto May 1987 A
4681117 Brodman et al. Jul 1987 A
4686085 Osterholm Aug 1987 A
4689041 Corday et al. Aug 1987 A
4692148 Kantrowitz et al. Sep 1987 A
4697574 Karcher et al. Oct 1987 A
4704102 Guthery Nov 1987 A
4705507 Boyles Nov 1987 A
4714460 Calderon Dec 1987 A
4721109 Healey Jan 1988 A
4722347 Abrams et al. Feb 1988 A
4722732 Martin Feb 1988 A
4723550 Bales et al. Feb 1988 A
4723936 Buchbinder et al. Feb 1988 A
4741328 Gabbay May 1988 A
4751924 Hammerschmidt et al. Jun 1988 A
4753637 Horneffer Jun 1988 A
4767409 Brooks Aug 1988 A
4770652 Mahurkar Sep 1988 A
4771777 Horzewski et al. Sep 1988 A
4777951 Cribier et al. Oct 1988 A
4785795 Singh Nov 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4790825 Bernstein et al. Dec 1988 A
4794928 Kletschka Jan 1989 A
4796629 Grayzel Jan 1989 A
4798588 Aillon Jan 1989 A
4804358 Karcher et al. Feb 1989 A
4804365 Litzie et al. Feb 1989 A
4808165 Carr Feb 1989 A
4809681 Kantrowitz et al. Mar 1989 A
4811737 Rydell Mar 1989 A
4821722 Miller et al. Apr 1989 A
4823812 Eshel et al. Apr 1989 A
4830849 Osterholm May 1989 A
4848344 Sos et al. Jul 1989 A
4850969 Jackson Jul 1989 A
4865581 Lundquist et al. Sep 1989 A
4877031 Conway et al. Oct 1989 A
4877035 Bogen et al. Oct 1989 A
4878495 Grayzel Nov 1989 A
4883458 Shiber Nov 1989 A
4886507 Patton et al. Dec 1989 A
4889137 Kolobow Dec 1989 A
4898168 Yule Feb 1990 A
4902272 Milder et al. Feb 1990 A
4902273 Choy et al. Feb 1990 A
4911163 Fina Mar 1990 A
4917667 Jackson Apr 1990 A
4923450 Maeda et al. May 1990 A
4927412 Menasche May 1990 A
4934996 Mohl et al. Jun 1990 A
RE33258 Onik et al. Jul 1990 E
4943275 Stricker Jul 1990 A
4943277 Bolling Jul 1990 A
4960412 Fink Oct 1990 A
4966604 Reiss Oct 1990 A
4969470 Mohl et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4985014 Orejola Jan 1991 A
4986830 Owens et al. Jan 1991 A
4990143 Sheridan Feb 1991 A
4994032 Sugiyama et al. Feb 1991 A
4994033 Shockey et al. Feb 1991 A
5007896 Shiber Apr 1991 A
5009636 Wortley et al. Apr 1991 A
5011468 Lundquist et al. Apr 1991 A
5011469 Buckberg et al. Apr 1991 A
5011488 Ginsburg Apr 1991 A
5013296 Buckberg et al. May 1991 A
5021044 Sharkaway Jun 1991 A
5021045 Buckberg et al. Jun 1991 A
5024668 Peters et al. Jun 1991 A
5026366 Leckrone Jun 1991 A
5033998 Corday et al. Jul 1991 A
5041093 Chu Aug 1991 A
5041098 Loiterman et al. Aug 1991 A
5047041 Samuels Sep 1991 A
5049132 Shaffer et al. Sep 1991 A
5053008 Bajaj Oct 1991 A
5059167 Lundquist et al. Oct 1991 A
5069661 Trudell Dec 1991 A
5069662 Bodden Dec 1991 A
5073168 Danforth Dec 1991 A
5088984 Fields Feb 1992 A
5089015 Ross Feb 1992 A
5090960 Don Michael Feb 1992 A
5106368 Uldall et al. Apr 1992 A
5109859 Jenkins May 1992 A
5112305 Barath et al. May 1992 A
5116305 Milder et al. May 1992 A
5125903 McLaughlin et al. Jun 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5167628 Boyles Dec 1992 A
5171232 Castillo et al. Dec 1992 A
5176619 Segalowitz Jan 1993 A
5181518 McDonagh Jan 1993 A
5186713 Raible Feb 1993 A
5195942 Weil et al. Mar 1993 A
5197952 Marcadis et al. Mar 1993 A
5216032 Manning Jun 1993 A
5219326 Hattler Jun 1993 A
5226427 Buckberg et al. Jul 1993 A
5236413 Feiring Aug 1993 A
5246007 Frisbie et al. Sep 1993 A
5250038 Melker et al. Oct 1993 A
5250069 Nobuyoshi et al. Oct 1993 A
5254089 Wang Oct 1993 A
5254097 Schock et al. Oct 1993 A
5270005 Raible Dec 1993 A
5275622 Lazarus et al. Jan 1994 A
5290231 Marcadis et al. Mar 1994 A
5295958 Shturman Mar 1994 A
5308320 Safar et al. May 1994 A
5312344 Grinfeld et al. May 1994 A
5314418 Takano et al. May 1994 A
5322500 Rickerd Jun 1994 A
5322509 Johnson et al. Jun 1994 A
5324260 O'Neill et al. Jun 1994 A
5330451 Gabbay Jul 1994 A
5334142 Paradis Aug 1994 A
5370618 Leonhardt Dec 1994 A
5370640 Kolff Dec 1994 A
5374245 Mahurkar Dec 1994 A
5380282 Burns Jan 1995 A
5382239 Orr et al. Jan 1995 A
5383854 Safar et al. Jan 1995 A
5385548 Williams et al. Jan 1995 A
5395330 Marcadis et al. Mar 1995 A
5395331 O'Neill et al. Mar 1995 A
5397306 Nobuyoshi et al. Mar 1995 A
5401241 Delany Mar 1995 A
5411027 Wiklund et al. May 1995 A
5411479 Bodden May 1995 A
5411552 Andersen et al. May 1995 A
5421825 Farcot Jun 1995 A
5425708 Nasu Jun 1995 A
5428070 Cooke et al. Jun 1995 A
5433700 Peters Jul 1995 A
5437633 Manning Aug 1995 A
5439443 Miyata et al. Aug 1995 A
5443446 Shturman Aug 1995 A
5451207 Yock Sep 1995 A
5453076 Kiyota et al. Sep 1995 A
5456665 Postell et al. Oct 1995 A
5458574 Machold et al. Oct 1995 A
5478309 Sweezer et al. Dec 1995 A
5487730 Marcadis et al. Jan 1996 A
5499996 Hill Mar 1996 A
5505698 Booth et al. Apr 1996 A
5509897 Twardowski et al. Apr 1996 A
5525388 Wand et al. Jun 1996 A
5527292 Adams et al. Jun 1996 A
5533957 Aldea Jul 1996 A
5562606 Huybregts Oct 1996 A
5578010 Ashby Nov 1996 A
5584803 Stevens et al. Dec 1996 A
5591129 Shoup et al. Jan 1997 A
5595181 Hubbard Jan 1997 A
5597377 Aldea Jan 1997 A
5599329 Gabbay Feb 1997 A
5613948 Avellanet Mar 1997 A
5766151 Valley et al. Jun 1998 A
5928192 Maahs Jul 1999 A
5980503 Chin Nov 1999 A
6010479 Dimitri Jan 2000 A
6210365 Afzal Apr 2001 B1
Foreign Referenced Citations (29)
Number Date Country
2246526 Mar 1973 DE
0 161 045 Nov 1985 EP
0 218 275 Apr 1987 EP
0 238 106 Sep 1987 EP
0 249 338 Dec 1987 EP
0 277 367 Aug 1988 EP
0 321 614 Jun 1989 EP
0 335 205 Oct 1989 EP
0 414 350 Feb 1991 EP
1097881 Jan 1968 GB
1097882 Jan 1968 GB
1284701 Aug 1972 GB
1414344 Nov 1975 GB
1467976 Mar 1977 GB
1477665 Jun 1977 GB
1513918 Jun 1978 GB
334404 Jan 1936 IT
1271508 Nov 1986 SU
1371701 Feb 1988 SU
WO 8103613 Dec 1981 WO
WO 8303204 Sep 1983 WO
WO 8910155 Nov 1989 WO
WO 9101689 Feb 1991 WO
WO 9108791 Jun 1991 WO
WO 9110456 Jul 1991 WO
WO 9117720 Nov 1991 WO
WO 9217118 Oct 1992 WO
WO 9307927 Apr 1993 WO
WO 9530447 Nov 1995 WO
Non-Patent Literature Citations (58)
Entry
Baxter Healthcare Corporation, “Fogarty Occlusion Catheter: Instructions for Use,” ©1994.
Buckberg, G.D., “Strategies and Logic of Cardioplegic Delivery to Prevent, Avoid, and Reverse Ischemic and Reperfusion Damage,” J Thorac Vasc Surg, 1987; 93:127-129.
Corday, et al., “Symposium on the Present Status of Reperfusion of the Acutely Ischemic Myocardium. Part I,” J. Am Coll Cardiol, 1983; 1(4):1031-1036.
Cosgrove, “Management of the Calcified Aorta: An Alternative Method of Occlusion,” Ann Thorac Surg, 1983;36:718-719.
Crooke, et al., “Biventricular Distribution of Cold Blood Cardioplegic Solution Administered by Different Retrograde Techniques,” J Cardiac Thorac Surg, 1991;102(4):631-636.
Datascope FDA 510(k) Application, “Percluder-DL Occluding Balloon,” Oct. 12, 1993.
DLP, Inc., Directions for Use: Cardioplegic Pressure Cannula with Vent Line, Code #24009 9 Gauge (no date).
DLP Medtronic Alternative Access Cannulae Brochure, ©1995.
DLP Worldwide Medical Innovations, Instrument Listings, pp. 5-9.
Douville, et al., “Retrograde Versus Antegrade Cardioplegia: Impact on Right Ventricular Function,” Ann Thorac Surg, 1992; 54:56-61.
Drinkwater, et al., “The Use of Combined Antegrade-Retrograde Infusion of Blood Cardioplegic Solution in Pediatric Patients Undergoing Heart Operations,” Thorac and Cardiovascular Surg, 1992; 104(5):1349-1355.
Elecath, “Baim Coronary Sinus Flow Catheter for Jugular or Subclavian Entry,” Catalog No. 75-2337, 1994.
Erath and Stoney, “Balloon Catheter Occlusion of the Ascending Aorta,” Ann Thorac Surg, 1983;35:560-561.
Farcot, et al., “New Catheter-Pump System for Diastolic Synchronized Coronary Sinus Retroperfusion (D.S.R.),” Med Prog Technol, 1980; 8(1):29-37.
Farcot, et al., “Synchronized Retroperfusion of Coronary Veins for Circulatory Support of Jeopardized Ischemic Myocardium,” Am J Cardiol, 1978; 41:1101-1201.
Foster and Threlkel, “Proximal Control of Aorta with a Balloon Catheter,” Surg Gynecology & Obstetrics, 1971, pp. 693-694.
Gundry, et al., “A Comparison of Retrograde of Cardioplegia Versus Antegrade Cardioplegia in the Presence of Coronary Artery Obstruction,” Ann Thorac Surg, 1984; 38(2):124-127.
Gundry, “Modification of Myocardial Ischemic in Normal and Hypertrophied Hearts Utilizing Diastolic Retroperfusion of the Coronary Veins,” J Thorac Cardiovasc Surg, 1982; 83:659-669.
Haendchen, et al., “Prevention of Ischemic Injury and Early Reperfusion Derangements by Hypothermic Retroperfusion,” J Am Coll Cardiol, 1983; 1(4):1067-1080.
Hammond, et al., “Retrograde Coronary Sinus Perfusion: A Method of Myocardial Protection in the Dog During Left Coronary Artery Occlusion,” Ann Surg, 1967; 166(1):139-147.
Ishizaka, “Myocardial Protection by Retrograde Cardiac Perfusion with Cold Medified Krebs Solution through Coronary Sinus During Complete Ischemic Arrest for 120 Minutes,” J Jpn Assn Thorac Surg, 1977;25(12);:1592-1601.
Kalmbach, et al., “Cardioplegia Delivery by Combined Aortic Root and Coronary Sinus Perfusion,” Ann Thorac Surg, 1989; 47:316-317.
Kar and Nordlander, “Coronary Veins: An Alternate Route to Ischemic Myocardium,” Heart and Lung, Mar. 1992, vol. 21, No. 2, pp. 148-155.
Leggett, et al., “Fiberoptic Cardioscopy Under Cardiopulmonary Bypass: Potential for Cardioscopy Surgery?” Ann Thorac Surg, 1994;58:222-225.
Lust, et al., “Improved Protection of Chronically Inflow-limited Myocardium with Retrograde Coronary Sinus Cardioplegia,” Circulation III, 1988;78(5):217-223.
Markov, et al., “Reversal of Acute Myocardial Ischemia in Closed Chest Animals by Retrograde Perfusion of the Coronary Sinus with Arterial Blood,” Acta Cardiologica, 1976; XXXI(3):185-199.
Medex, Inc. Product Brochure, Angioplasty Kits and Accessories and PTCA Valve, 1990.
Medex, Inc., MX220 Single Tuohy-Borst Adaptor: Instructions for Use, 1992.
Medi-Tech, Boston Scientific Corporation, “Occlusion Balloon Catheters: Instructions for Use,” Rev. Jun., 1991.
Medtronic Bio-Medicus, Inc., “Bio-Medicus Cannula Instructions for Use Manual, Sterile and Non-Pyrogenic Single-Use Only,” PN 85281 Rev C(10-91).
Medtronic Bio-Medicus, Inc., “Bio-Medicus Cannula Introducer Instructions for Use Manual,” PN 85146-Rev. C(7/91).
Medtronic Bio-Medicus Femoral Cannulae advertisement, ©1991.
Medtronic Bio-Medicus Pediatric Cannulae advertisement, ©1991.
Medtronic Bio-Medicus Percutaneous Cannula Kits advertisements, ©1991.
Meerbaum, et al., “Diastolic Retroperfusion of Acutely Ischemic Myocardium,” AM J Cardiol, 1976; 37:588-598.
Meerbaum, et al., “Hypothermic Coronary Venous Phased Retroperfusion: A Closed-Chest Treatment of Acute Regional Mycardial Ischemia,” Circulation, 1982; 65(7): 1435-1445.
Meerbaum, et al., “Retrograde Lysis of Coronary Artery Thrombus by Coronary Venouse Strepokinase Administration,” J Am Coll Cardiol, 1983; 1(5):1262-1267.
Menasche, et al., “Cardioplegia by Way of the coronary Sinus for Valvular and Coronary Surgery,” JACC, 1991; 18(2):628-636.
Menasche, et al., “Retrograde Cardioplegia through the Coronary Sinus,” Ann Thorac Surg, 1987; 44:214-216.
Menasche, et al., “Retrograde Coronary Sinus Cardioplegia for Aortic Valve Operations: A Clinical Report on 500 Patients,” Ann Thorac Surg, 1990; 49:556-564.
Menasche, et al., “Retrograde Warm Blood Cardioplegia Preserves Hypertrophied Myocardium: A Clinical Study,” Ann Thorac Surg, 1994; 57:1429-1435.
“Valvular Heart Disease,”Merck Manual of Diagnosis and Therapy, sixteenth ed, 1992, pp. 546-553.
Ogawa, K. “Aortic Archa Reconstruction Without Aortic Cross-Clamping Using Separate Extracorporeal Circulation,” J Jpn Assn Thorac Surg, 1993; pp. 2185-2190.
Okita, et al., “Utilization of Triple-Lumen Balloon Catheter for Occlusion of the Ascending Aorta During Distal Aortic Arch Surgery with Hypothermic Retrograde Cerebral Circulation Technique Through Left Thoracotomy,” Journal of Cardiac Surgery, 1996; 10:699-702.
Peters, W. S., “The Promise of Cardioscopic Surgery,” AustralAs J Cardiac Thorac Surg, 1993; 2(2):152-154.
Pilling Surgical Instruments, vascular Clamps—Cooley Brochure, p. 385 (no date).
Razi, D..M., “The Challenge of Calcific Aortitis,” J Cardiac Surg, 1993; 8:102-107.
Reseach Medical, Inc., Cardioplegia Products, Product Catalog 1995.
Research Medical, Inc., Fem Flex Femoral Percutaneous Cannulae, advertisement, Ann Thorac Surg, Jan., 1995, p. A38.
Ropchan, et al., “Salvage of Ischemic Myocardium by Nonsynchronized Retroperfusion in the Pig,” The Journal of Thoracic and Cardiovascular—Surgery, Sep. 1992, vol. 104, No. 3, pp. 619-625.
Rossi, “Long-term Cardiopulmonary Bypass by Peripheral Cannulation in a Model of Total Heart Failure,” J Thorac Cardiac Vasc Surg, 1990; 100:914-921.
Sabiston, D.C., Textbook of Surgery, 10th Ed., 1972, pp. 2021-2023, 2114-2121.
Sakaguchi et al, “Aortic Valve Replacement and Coronary Artery Bypass,” J Jpn Assoc for Thoracic Surg, 1993;41(6):1063-1068.
Shumway, “Forward Versus Retrograde Coronary Perfusion for Direct Vision Surgery of Acquired Aortic Valvular Disease,” J Thoracic and—Cardiovasc Surg, 1959; 75-80.
Takahashi, M., “Retrograde Coronary Sinus Perfusion for Myocardial protection in Aortic A valve Surgery,” J Jpn Assn Thorac Surg, 1982;30(3):306-318.
Uchida et al., “Percutaneous Cardiomyotomy as Valvulotomy with Angioscopic Guidance,” American Heart Journal, 1991;121(4, part I):1221-1224.
Uchida, et al., “Percutaneous Fiberoptic Angioscopy of the Cardiac Valves,” Am Heart J, 1991;121(6, part I):1791-1798.
Yamaguchi, A., “A Case of Reoperation Using a Balloon Catheter with Blocked Pars Ascendes Aortae,” Kyobu Geka, Oct. 1989; 42(11):961-964.
Continuations (1)
Number Date Country
Parent 09/012833 Jan 1998 US
Child 09/685383 US